Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity
· seekingalpha.com
Ocular Therapeutix's AXPAXLI's strong Phase 3 SOL-1 results support a clear regulatory path, with NDA filing expected in Q4. See why I rate OCUL stock a Buy.
Ocular Therapeutix ( OCUL ) closed at $6.61 on Thursday, close to its 52-week low of $6.00 and well below the $16.44 high. For a company that reported one of th...